Abivax S.A. — Investor Relations & Filings
Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms. The company's core strategy revolves around modulating the immune response through microRNA (miRNA). Its lead drug candidate, obefazimod, is an investigational, orally administered small molecule with a novel mechanism of action. Obefazimod is designed to enhance the expression of miR-124, a key microRNA that regulates the inflammatory response. The primary development goal is the commercialization of obefazimod for the treatment of ulcerative colitis, with clinical programs also underway for Crohn's disease. The company is exploring obefazimod for other inflammatory indications and is investigating follow-on compounds from its proprietary chemical library.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 6-K | 2026-05-22 | English | |
| 6-K | 2026-05-20 | English | |
| 6-K - Abivax S.A. (0001956827) (Filer) | 2026-05-07 | English | |
| 424B7 - Abivax S.A. (0001956827) (Filer) | 2026-05-07 | English | |
| S-8 - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English | |
| 20-F - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English |
Browse filings by year
5 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
10 filings
| |||||
| 46859106 | 6-K | 2026-05-22 | English | ||
| 46692793 | 6-K | 2026-05-20 | English | ||
| 43481539 | 6-K - Abivax S.A. (0001956827) (Filer) | 2026-05-07 | English | ||
| 43132807 | 424B7 - Abivax S.A. (0001956827) (Filer) | 2026-05-07 | English | ||
| 33016665 | S-8 - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English | ||
| 33016505 | 20-F - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English | ||
| 33016424 | 6-K - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English | ||
| 32249312 | SCHEDULE 13G/A Filing | 2026-02-13 | English | ||
| 13630008 | Major Shareholding Notification 2026 | 2026-01-14 | English | ||
| 13630005 | Regulatory Filings 2026 | 2026-01-08 | English | ||
|
2025
5 filings
| |||||
| 13630007 | 6-K | 2025-12-15 | English | ||
| 13630010 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 13630009 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 13630012 | Major Shareholding Notification 2025 | 2025-10-30 | English | ||
| 13630011 | Regulatory Filings 2025 | 2025-10-28 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
cbdMD, Inc.
Producer and distributor of health and wellness CBD product…
|
YCBD | US | Manufacturing |
|
CCSB
Specialized manufacturer of APIs for oncology, antifungal, …
|
1762 | TW | Manufacturing |
|
CDT Equity Inc.
A clinical-stage biopharmaceutical firm advancing assets fo…
|
CDT | US | Manufacturing |
|
Ceapro Inc.
Develops and commercializes natural active ingredients deri…
|
CZO | CA | Manufacturing |
|
CELADON PHARMACEUTICALS PLC
Researches, cultivates, and manufactures cannabinoid-based …
|
CEL | GB | Manufacturing |
|
Celemics, Inc.
Develops NGS target enrichment solutions for research and c…
|
331920 | KR | Manufacturing |
|
Cellbion Co., Ltd
Develops radiopharmaceuticals and radioligand therapies for…
|
308430 | KR | Manufacturing |
|
CELL BIOTECH CO ., LTD
Develops and manufactures probiotic solutions using patente…
|
049960 | KR | Manufacturing |
|
Celldex Therapeutics, Inc.
Develops antibody-based immunotherapies for severe inflamma…
|
CLDX | US | Manufacturing |
|
Cellectar Biosciences, Inc.
Clinical-stage biopharma developing targeted cancer treatme…
|
CLRB | US | Manufacturing |
Abivax S.A. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/30868/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=30868 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=30868 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=30868 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 30868}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Abivax S.A. (id: 30868)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.